

Bora Pharmaceuticals Reports Consolidated Revenue of NT\$1.66 Billion in December

保瑞公告 12 月自結合併營收新台幣 16 億 6 仟萬元

Taipei, Taiwan, January 9, 2026 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”) announced that its consolidated revenues for December 2026 reached NT\$1.66 billion, existing 2025 with a 2.7% increase in full year net revenues compared to 2024. In functional currency (USD), the increase was 5.8%. 2025 CDMO revenues, including internal orders, increased by 53.8% year over year, with particularly strong performance in December from the Canada and Zhunan sites. In addition, Bora’s Canadian facility was also able to re-sign one of its largest long term commercial contracts with one of its anchor customers, reaffirming Bora’s continued and strategic investment into that facility. In parallel, Specialty Pharma portfolio, part of Bora’s pharma sales business, reached an all-time high in December, offsetting the impact of fewer working days

台北，台灣，2026 年 1 月 9 日 – 保瑞藥業（以下簡稱「保瑞」，股票代碼：6472）今日公告 12 月自結合併營收為新台幣 16 億 6 仟萬元，2025 年全年營收較去年增長 2.7%，若以美金計則增長為 5.8%。2025 年 CDMO 含內部訂單年增 53.8%，且加拿大廠及竹南廠 12 月表現相當強勁，而全球銷售業務的專科用藥產品線也於 12 月創下歷史新高，彌補了工作天數少的影響；由於 CDMO 業務的實績備受全球知名藥廠肯定，加拿大廠的重大客戶亦於 12 月時完成續約，將與保瑞 CDMO 網絡更加全面地攜手共進。

While the Company’s subsidiary continues to monitor bidding progress of DLS competitor, it is actively preparing to refill portfolio and pipeline from both internal and external resources. ScinoPharm Taiwan’s glatiramer acetate, a generic version of Copaxone® for the treatment of relapsing-remitting multiple sclerosis, received approval from the U.S. Food and Drug Administration on December 31, 2025, and will be commercialized in the United States by Bora’s subsidiary in accordance with the parties’ commercialization agreement. According to IQVIA, the current annual market size for glatiramer acetate is approximately US\$557 million.

美國子公司除持續關注取得 DLS 學名藥藥證的新進競爭者的上市策略，亦積極展開學名藥業務止血後新一輪產品組合與在研產品布局，同步導入內部及外部資源以強化未來成長動能。日前台灣神隆用於治療多發性硬化症的 glatiramer acetate (Copaxone® 之學名藥) 已於 2025 年 12 月 31 日取得美國食品藥物管理局 (FDA) 核准，並將依雙方既有的商業化協議由保瑞集團子公司負責於美國市場上市；根據 IQVIA，glatiramer acetate 在美國的市場約 5.57 億美元。

Bobby Sheng, Chairman of Bora Group, said that the launch “reflects our repositioned focus on complex medicines and the commitment to delivering accessible, high-quality healthcare solutions, while underscoring the growing importance of R&D partners as key stakeholders.” Looking ahead, Bora will strengthen its U.S. pharmaceutical portfolio by investing in more specialized distribution channels and expanding into higher-complexity dosage forms, with 2026 focused on rebuilding a de-risked, long-tail portfolio foundation to support

sustainable growth in the U.S. market.

保瑞集團董事長盛保熙表示，保瑞在新年伊始展現重新聚焦於高複雜度藥品的產品策略，以及其致力於提供可近性高、品質優良醫療解決方案的承諾，同時也突顯研發夥伴作為關鍵利害關係人的重要性。展望未來，保瑞將持續投入更專精的通路布局及拓展高複雜度的劑型，透過分散風險、建立長尾效應雙管齊下，重塑並強化在美藥品銷售組合。

Bora will attend the 44th J.P. Morgan Healthcare Conference in San Francisco next week. On January 15, the Company will host a corporate presentation and conduct one-on-one meetings with institutional investors. Chairman Bobby Sheng noted that Bora has officially commenced trading on the U.S. OTCQX Market, adding that participating in the conference with deeper access to U.S. institutional and public investors marks an important chapter in Bora's global expansion. "We look forward to carry forward the strong engagement and support from the Taiwan market to OTCQX as Bora continues to advance our international visibility", Bobby commented.

保瑞將於下周於美國舊金山參加 JP Morgan 第 44 屆健康醫療大會，並於 1 月 15 日進行公司簡報以及與機構投資者進行面對面會議，保瑞集團董事長盛保熙指出，保瑞已經正式於美國 OTCQX 市場開啟交易，「對於能以更深入美國機構與大眾投資人的面貌參與健康醫療大會是保瑞全球化的重要篇章」，他期待延續台灣市場對此進程的熱情，持續推進保瑞的國際能見度。

About Bora:

Founded in 2007, Bora Pharmaceuticals ("Bora" or "the Company", 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success "certain," Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:

<https://www.bora-corp.com>

<https://www.boracdm.com>

關於保瑞：

保瑞藥業股份有限公司（股票代碼：6472.TW與BORAY.OTCQX）成立於2007年，是一家領先的製藥服務公司，自成立伊始即秉持「為全世界健康貢獻力量」的願景與目標。保瑞以整合 CDMO（委託開發與製造服務）與藥物開發銷售的「雙引擎」商業模式，協助製藥與生技合作夥伴優化產品開發流程、加速上市時程、擴大供應規模以滿足全球患者的需求。公司亦專注於美國的利基市場及罕見疾病領域，致力於透過拓展銷售通路實力提升患者的生活品質。

透過持續投資人才、生產與銷售及進入生物製劑業務領域，保瑞不斷推動業務升級與永續發展。我們以Making Success More Certain為使命，專注高品



質、高效率與可靠性，在製藥及 CDMO 領域樹立新標杆。

請造訪：

企業網站 <https://www.bora-corp.com>

CDMO 網站 <https://www.boracdm.com>

Investor/Media enquiries 新聞聯繫人：

Nadiya Chen, Investor Relations 投資人關係 陳荻雅

+886 2 790-1555 Ext. 9108

Email : Nadiya.Chen@bora-corp.com